Free Trial
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:GNPX

Genprex 5/13/2026 Earnings Report

Genprex logo
$0.86 +0.01 (+1.20%)
Closing price 05/14/2026 04:00 PM Eastern
Extended Trading
$0.84 -0.02 (-2.71%)
As of 09:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Genprex EPS Results

Actual EPS
-$0.64
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Genprex Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Genprex Announcement Details

Quarter
Date
5/13/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Genprex Earnings Headlines

Genprex Announces Positive Preclinical Data for Diabetes Gene Therapy
May 14 at 8:51 AM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/genprex-announces-positive-preclinical-data-for-diabetes-gene-therapy?utm_source=marketbeat.com&utm_medium=referral
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
May 14 at 8:00 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-collaborators-present-positive-preclinical-data-on-diabetes-gene-therapy-for-type-2-diabetes-at-the-2026-american-society-of-gene-and-cell-therapy-annual-meeting-302771907.html
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
May 15 at 1:00 AM  |  American Alternative (Ad)
Genprex Expands Reqorsa Cancer Therapy Patent Protection in Israel
April 30, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/genprex-expands-reqorsa-cancer-therapy-patent-protection-in-israel?utm_source=marketbeat.com&utm_medium=referral
Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
April 30, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-receives-patent-grant-from-the-israel-patent-office-for-the-combination-of-reqorsa-gene-therapy-and-pd-1-antibodies-to-treat-cancer-302758043.html
Genprex Highlights Promising Preclinical Data for Diabetes Gene Therapy
April 28, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/genprex-highlights-promising-preclinical-data-for-diabetes-gene-therapy?utm_source=marketbeat.com&utm_medium=referral
See More Genprex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Genprex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genprex and other key companies, straight to your email.

About Genprex

Genprex (NASDAQ:GNPX), Inc. is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes. This preclinical program seeks to deliver genes that support insulin production and glucose regulation, laying the groundwork for future clinical development in metabolic diseases. By leveraging its gene delivery platform, the company aims to expand its pipeline into other oncology and metabolic indications over time.

Headquartered in Austin, Texas, Genprex operates under a management team with deep experience in gene therapy research and biopharmaceutical development. The company collaborates with leading academic and clinical research centers to conduct its studies, ensuring rigorous trial design and patient enrollment. Through these partnerships, Genprex seeks to translate cutting-edge genetic science into transformative therapies for patients with high-unmet medical needs.

View Genprex Profile
Earnings Tools